Reshaping Vascular Care

In May of 2022, Ryan Valle assumed the role of President of Azura Vascular Care, a nationwide network of outpatient and ambulatory surgery centers specializing in high-quality and minimally invasive vascular procedures. Ryan also serves as the Senior Vice President for Strategic Development for Fresenius Kidney Care (FKC), an affiliate of Azura and part of the Fresenius Medical Care global portfolio.

Immediately prior to assuming the role as President of Azura, he served as Senior Vice President of Strategic Development for FKC, and led an operational division created specifically to develop and implement strategies to improve the clinical and financial performance of the most challenged dialysis clinics in the portfolio. Ryan also spearheaded the comprehensive integration efforts of newly acquired clinics for the first-year post-closing.

Jennifer Delphia is Vice President of Portfolio Management & Operations for Emerging Businesses.  In that role Jennifer also provides leadership for Services & Operations at Frenova Renal Research and is the Executive Director for the My Reason renal research study.  She is a seasoned transformation leader with extensive experience in optimizing organizational performance.  Prior to joining Fresenius, Jennifer held various executive-level positions, including Vice President, Process Innovation & Transformation Leadership with Beacon Health Options and Vice President of Client Services at Neighborhood Diabetes.  Jennifer earned a BS in Business Administration from the University of New Hampshire and received her MBA from the University of Virginia, Darden Graduate School of Business.

Martin Ahlijanian leads Frenova’s global contracts formation and administration activities. Following his graduation from the Catholic University of America with a Juris Doctor degree, Martin spent the next 30 years in various contracts, legal and compliance functions across both public and private sectors, serving in the U.S., Europe and Middle East. He has supported colleagues, customers and partners with transactions involving healthcare informatics, professional services, consulting, and processing. Martin has lead teams as large as 24 professionals, with a specific focus on colleagues’ professional development and engagement. As Frenova’s Senior Director, Contracts Administration, Martin is responsible for the effective creation and management of Frenova’s agreements and the employment of best practices and new technologies, including AI, to more efficiently close and deliver high value opportunities with the lowest possible risk for the organization.  

Jan Walter leads FRENOVA and FMC’s Emerging Businesses Unit. Goal of the Emerging Businesses is to accelerate the development of FMC’s strategic investments in new therapies and technologies and to mature FRENOVA’s service offerings as a Site Management Organization. He previously served as senior vice president for Fresenius Medical Care in Central Asia Pacific with commercial and legal responsibilities for a mix of mature and emerging markets, including Korea, India, the Philippines, Bangladesh, and Pakistan. He is the former managing director for Fresenius Kabi in Southeast Asia, and began his career with Fresenius SE and CO KGaA as assistant to the chief executive officer. Jan graduated with dual master’s degrees in business administration and economics from the University of Leipzig in Germany and holds his MBA from Binghamton University in New York.

Dr. Arens has nearly three decades of experience in the pharma and medtech industries.

He uses his expertise to involve himself in directing international study budgets, negotiating contracts, and supporting clients with medical and operational leadership as well as consulting for solutions clients are looking for.

With a substantial number of publications to his credit, he held various positions in drug clinical research and development at Takeda, Merck KGaA, and Abbott/AbbVie, with responsibility for global clinical development teams as well as the strategic development of companion diagnostic and biomarker approaches connecting diagnostics and pharma in the field of personalized medicine. He joined Fresenius Medical Care in 2010, starting to serve as Director of Medical Affairs at Fresenius Renal Pharmaceuticals International, thereby managing medical and scientific support for the entire product portfolio of the Renal Pharma branch until 2016.

Eddie Hedrick leads the global technology strategy and development domain for Frenova.  As a health information technology leader, he has an accomplished track record and extensive experience in many facets of technology and application development, deployment and support.  He has previously led software development strategy and operations in electronic health record applications, as well as the acquisition and growth of additional software product suites.  His experience with Fresenius Medical Care has also included leadership in the national health information exchange strategy.

As Frenova’s technology executive, he leads all aspects of technology for Frenova’s service offerings, by embracing new and innovative technologies to steer the organization toward better efficiency and performance.  Eddie also leads the technology strategy, design and development of the Kidney Genomics Research and Discovery (GRAND) Initiative, the My Reason Research Program.